



東京大学公共政策大学院 Graduate School of Public Policy, The University of Tokyo
2020年度度 第9回医療技術評価国際シンポジウム 9th International HTA Symposium
「新型コロナパンデミックと医療技術評価の役割」 – Covid-19 Pandemic and Role of Health Technology Assessment –
2021年3月2日オンライン開催 2nd March 2021, ONLINE

背景と論点

Background and Agenda Today

東京大学公共政策大学院「医療政策・技術評価」研究プロジェクト特任教授
キヤノングローバル戦略研究所研究主幹
国際学会ISPOR次期会長
鎌江伊三夫

Project Professor, Health Policy and Technology Assessment, GraSPP, UTokyo
Research Director, Canon Institute for Global Studies
ISPOR President-elect
Isao Kamae, MD, DrPH



Total Cases
114,350,611

Total Deaths
2,536,865

192
 countries/regions



Covid-19 in
 the world
 As of
 March 1, 2021

Covid-19 pandemic: Where are we?

- Initial public-health and medical response in testing, tracing, isolation, and treatments
- Non-medical interventions: physical distancing, event closures and lockdown of the cities
- New Normal with but against the coronavirus
 - wearing a face mask and protective behavioral changes
 - virtual and home-based approaches in business and public services
 - financial support for affected individuals and industries
- Repeated surges and the capacity building in supply chain management of equipment, non-hospital care for mild to moderate cases, and ICU/ventilator care for severe cases
- Hope of containment: vaccination began in some countries, but still uncertainty with variants.

Key policy areas for HEOR/HTA

Value assessment of vaccines, diagnostics and therapeutics

Socio-economic analysis and guidance development for decision making beyond epidemiological modeling

Informed decision making for lockdown and reopening

Capacity management in supply chains and distribution

Long-term Covid-19 management

Mitigation and resilience for Pandemic X in the future

第9回医療技術評価国際シンポジウム

9th HTA International Symposium in UTokyo

「新型コロナパンデミックと医療技術評価の役割」

Covid-19 Pandemic and Role of Health Technology Assessment

①海外からの招待講演
各国のCOVID-19事情
Invited lectures from
Sweden, France and
Taiwan

②日本のCOVID-19対策
Case in Japan and MHLW

総合討論
ウイズコロナ時代に医療技術評価が果たすべき役割
Role of Health Technology Assessment in the era
with Covid-19

Invited Speakers

16:30-17:00 Lecture 1: Case Report 1 from Europe – Covid-19 pandemic and Health Economics in Sweden

Ulf Persson, senior advisor, The Swedish Institute for Health Economics

17:00-17:30 Lecture 2: Case Report 2 from Europe – Covid-19 pandemic and Health Economics in France

Pierre-Yves Geoffard, professor, Paris School of Economics

17:30-18:00 Lecture 3: Case Report from Asia – Covid-19 pandemic and HTA in Taiwan

Raoh-Fang Jasmine Pwu, director, National Hepatitis C Program Office, Ministry of Health and Welfare, Taiwan

Board of Director (2018-2021), ISPOR

18:00-18:30 Lecture 4: Case Report from Japan – Covid-19 pandemic and HTA in Japan

Yasuhiro Suzuki, Ministry of Health, Labor and Welfare Advisor (Former Chief Medical and Global Health Officer, Ministry of Health, Labor and Welfare, Japan)

Topics in
panel
discussion
would
include ...

- Difference of policy in countries across the world
- Communication gaps between health professionals and decision makers
- How to solve the dilemma btw containing the spread of epidemic vs. maintaining economic activities
- Value assessment of interventions:
 - standardization of testing, optimal testing
 - value of vaccination and drugs for treatment
- Role of value assessment in the era with Covid-19

Gap between perception and science

Myth(perception of people)

- PCR test positive means 'infected.'
- The more testing, the better containing the virus spreading.
- PCR test positive is universal in any countries.
- The PCR test negative certificate can work for prevention.
- Vaccination terminates the pandemic.

Truth(scientific interpretation)

- Statistical errors caused by test sensitivity and specificity
- False negatives overlooked, while false positives ethically unfavorable.
- The Ct value, a threshold for being positive, might vary from country to country.
- It may not necessarily prove 'true negative', and misleading without any Ct-value standardization.
- Insufficient evidence on safety and efficacy in the real world.

HTA is not just about pricing,
but science on value.

Thank you for your attention.



ISAO KAMAE

kamae@pp.u-tokyo.ac.jp